FATE logo

Fate Therapeutics (FATE) Cash From Operations

Annual CFO

-$122.87 M
+$9.39 M+7.10%

December 31, 2024


Summary


Performance

FATE Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherFATEcash flowmetrics:

Quarterly CFO

-$27.80 M
+$1.62 M+5.51%

December 31, 2024


Summary


Performance

FATE Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherFATEcash flowmetrics:

TTM CFO

-$122.87 M
+$8.84 M+6.71%

December 31, 2024


Summary


Performance

FATE TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherFATEcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

FATE Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+7.1%+5.5%+6.7%
3 y3 years+24.6%+5.5%+6.7%
5 y5 years-47.7%+5.5%+6.7%

FATE Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+50.5%at high+63.1%at high+50.5%
5 y5-year-213.2%+50.5%-171.6%+63.1%-270.1%+50.5%
alltimeall time-911.7%+50.5%-171.6%+63.1%-3024.2%+50.5%

Fate Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$122.87 M(-7.1%)
-$27.80 M(-5.5%)
-$122.87 M(-6.7%)
Sep 2024
-
-$29.42 M(-8.9%)
-$131.71 M(-6.3%)
Jun 2024
-
-$32.31 M(-3.1%)
-$140.57 M(+2.8%)
Mar 2024
-
-$33.35 M(-9.0%)
-$136.75 M(+3.4%)
Dec 2023
-$132.26 M(-46.7%)
-$36.64 M(-4.3%)
-$132.26 M(-22.7%)
Sep 2023
-
-$38.27 M(+34.3%)
-$171.01 M(-8.9%)
Jun 2023
-
-$28.49 M(-1.3%)
-$187.79 M(-11.6%)
Mar 2023
-
-$28.86 M(-61.7%)
-$212.46 M(-14.4%)
Dec 2022
-$248.21 M(+52.4%)
-$75.39 M(+37.0%)
-$248.21 M(+2.1%)
Sep 2022
-
-$55.05 M(+3.6%)
-$243.11 M(+9.8%)
Jun 2022
-
-$53.16 M(-17.7%)
-$221.44 M(+10.5%)
Mar 2022
-
-$64.61 M(-8.1%)
-$200.39 M(+23.0%)
Dec 2021
-$162.87 M(+315.2%)
-$70.29 M(+110.6%)
-$162.87 M(+43.8%)
Sep 2021
-
-$33.38 M(+4.0%)
-$113.24 M(+2.4%)
Jun 2021
-
-$32.11 M(+18.5%)
-$110.60 M(+178.9%)
Mar 2021
-
-$27.10 M(+31.1%)
-$39.65 M(+1.1%)
Dec 2020
-$39.23 M(-52.8%)
-$20.66 M(-32.8%)
-$39.23 M(-11.0%)
Sep 2020
-
-$30.73 M(-179.1%)
-$44.10 M(+32.8%)
Jun 2020
-
$38.84 M(-245.6%)
-$33.20 M(-64.0%)
Mar 2020
-
-$26.67 M(+4.5%)
-$92.36 M(+11.0%)
Dec 2019
-$83.17 M(+115.2%)
-$25.54 M(+28.7%)
-$83.17 M(+21.1%)
Sep 2019
-
-$19.84 M(-2.3%)
-$68.66 M(+31.1%)
Jun 2019
-
-$20.31 M(+16.1%)
-$52.38 M(+20.2%)
Mar 2019
-
-$17.49 M(+58.7%)
-$43.59 M(+12.8%)
Dec 2018
-$38.65 M
-$11.02 M(+209.9%)
-$38.65 M(+0.8%)
DateAnnualQuarterlyTTM
Sep 2018
-
-$3.56 M(-69.1%)
-$38.35 M(-13.9%)
Jun 2018
-
-$11.52 M(-8.2%)
-$44.56 M(+6.3%)
Mar 2018
-
-$12.55 M(+17.1%)
-$41.91 M(+13.8%)
Dec 2017
-$36.82 M(+23.5%)
-$10.72 M(+9.7%)
-$36.82 M(+9.4%)
Sep 2017
-
-$9.77 M(+10.1%)
-$33.65 M(+7.2%)
Jun 2017
-
-$8.87 M(+19.0%)
-$31.39 M(+4.6%)
Mar 2017
-
-$7.46 M(-1.3%)
-$30.03 M(+0.7%)
Dec 2016
-$29.82 M(+62.1%)
-$7.55 M(+0.5%)
-$29.82 M(+2.0%)
Sep 2016
-
-$7.52 M(+0.2%)
-$29.24 M(+1.3%)
Jun 2016
-
-$7.50 M(+3.5%)
-$28.86 M(+49.7%)
Mar 2016
-
-$7.25 M(+4.0%)
-$19.27 M(+4.8%)
Dec 2015
-$18.40 M(-17.9%)
-$6.97 M(-2.3%)
-$18.40 M(+4.6%)
Sep 2015
-
-$7.13 M(-443.0%)
-$17.58 M(+10.1%)
Jun 2015
-
$2.08 M(-132.6%)
-$15.97 M(-32.2%)
Mar 2015
-
-$6.38 M(+3.6%)
-$23.54 M(+5.0%)
Dec 2014
-$22.42 M(+45.8%)
-$6.15 M(+11.5%)
-$22.42 M(+7.6%)
Sep 2014
-
-$5.52 M(+0.6%)
-$20.84 M(+10.9%)
Jun 2014
-
-$5.49 M(+4.5%)
-$18.79 M(+12.6%)
Mar 2014
-
-$5.25 M(+14.8%)
-$16.70 M(+8.6%)
Dec 2013
-$15.37 M(+15.8%)
-$4.58 M(+31.9%)
-$15.37 M(+42.4%)
Sep 2013
-
-$3.47 M(+2.4%)
-$10.79 M(+47.4%)
Jun 2013
-
-$3.39 M(-13.8%)
-$7.32 M(+86.2%)
Mar 2013
-
-$3.93 M
-$3.93 M
Dec 2012
-$13.27 M(+9.3%)
-
-
Dec 2011
-$12.14 M
-
-

FAQ

  • What is Fate Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Fate Therapeutics?
  • What is Fate Therapeutics annual CFO year-on-year change?
  • What is Fate Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Fate Therapeutics?
  • What is Fate Therapeutics quarterly CFO year-on-year change?
  • What is Fate Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Fate Therapeutics?
  • What is Fate Therapeutics TTM CFO year-on-year change?

What is Fate Therapeutics annual cash flow from operations?

The current annual CFO of FATE is -$122.87 M

What is the all time high annual CFO for Fate Therapeutics?

Fate Therapeutics all-time high annual cash flow from operations is -$12.14 M

What is Fate Therapeutics annual CFO year-on-year change?

Over the past year, FATE annual cash flow from operations has changed by +$9.39 M (+7.10%)

What is Fate Therapeutics quarterly cash flow from operations?

The current quarterly CFO of FATE is -$27.80 M

What is the all time high quarterly CFO for Fate Therapeutics?

Fate Therapeutics all-time high quarterly cash flow from operations is $38.84 M

What is Fate Therapeutics quarterly CFO year-on-year change?

Over the past year, FATE quarterly cash flow from operations has changed by +$1.62 M (+5.51%)

What is Fate Therapeutics TTM cash flow from operations?

The current TTM CFO of FATE is -$122.87 M

What is the all time high TTM CFO for Fate Therapeutics?

Fate Therapeutics all-time high TTM cash flow from operations is -$3.93 M

What is Fate Therapeutics TTM CFO year-on-year change?

Over the past year, FATE TTM cash flow from operations has changed by +$8.84 M (+6.71%)